1型糖尿病的药理疗法 - 第3部分:明天
Marc Rendell1,2
1The Association of Diabetes Investigators, Omaha, NE, USA.
Expert opinion on pharmacotherapy
|March 8, 2025
概括
1型糖尿病的管理已经从致命到通过胰岛素治疗得到控制. 新兴的治疗方法侧重于免疫抑制和β细胞再生,以寻求潜在的治疗方法.
科学领域:
- 内分泌学 在内分泌学.
- 免疫学 免疫学 免疫学
- 再生医学是一种再生医学.
背景情况:
- 1型糖尿病在历史上是致命的,但在上个世纪,胰岛素治疗改变了这种情况.
- 进步包括合成胰岛素,胰岛素和持续的葡萄糖监测,以改善血糖控制.
- 目前的研究重点是免疫抑制以防止β细胞破坏和潜在的β细胞替代疗法.
研究的目的:
- 审查1型糖尿病管理的历史进展和当前进展.
- 探索针对免疫系统和β细胞再生的新兴治疗策略.
- 讨论1型糖尿病治疗和潜在治疗的未来前景.
主要方法:
- 使用谷歌,微软和PubMed.com进行了全面的文献搜索.
- 分析了胰岛素治疗,葡萄糖监测和免疫调节治疗的关键发展.
- 评估了未来的治疗途径,包括基于细胞的疗法和先进的免疫抑制.
主要成果:
- 胰岛素治疗显著改善了结果,先进的输送系统接近正常的葡萄糖水平.
- 通过自身抗体和早期免疫干预 (例如, teplizumab) 来识别有风险的个体显示出有希望.
- 免疫抑制和β细胞替代是未来突破的关键领域.
结论:
- 在管理1型糖尿病方面取得了显著进展,朝着更好的血糖控制和预防迈进.
- 未来的疗法可能涉及有针对性的免疫抑制和再生方法,如干细胞衍生的β细胞,以寻求潜在的治疗方法.
- 免疫学和再生医学领域的持续研究有望改变1型糖尿病的治疗方法.
相关概念视频
Diabetes: Management and Pharmacotherapy
222
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
222
Insulin: Dosing Regimen and Adverse Effects
136
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
136
Diabetes Mellitus: Overview and Type I Subtype
2.3K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.3K
Carbohydrate Metabolism
10.7K
Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
10.7K
Diabetes Mellitus: Type 2 and Gestational
2.1K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.1K
Oral Hypoglycemic Agents: Biguanides and Glitazones
149
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
149


